Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Darunavir Combinations on Dabigatran PK in Healthy Subjects
NCT04208061Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Dec 2019; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04208061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208061.